Advances in development of biomarkers for brain damage and ischemia
Molecular Biology Reports · 2024-12 · 51 (1)
DOI: 10.1007/s11033-024-09708-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, online erschienen am 13.07.2024. Verfasst von Diana Karimova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala, University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Biomarkers, Brain Injuries, Brain Ischemia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uppsala University.
Abstract (Originalsprache)
Acquired brain injury is an urgent situation that requires rapid diagnosis and treatment. Magnetic resonance imaging (MRI) and computed tomography (CT) are required for accurate diagnosis. However, these methods are costly and require substantial infrastructure and specialized staff. Circulatory biomarkers of acute brain injury may help in the management of patients with acute cerebrovascular events and prevent poor outcome and mortality. The purpose of this review is to provide an overview of the development of potential biomarkers of brain damage to increase diagnostic possibilities. For this purpose, we searched the PubMed database of studies on the diagnostic potential of brain injury biomarkers. We also accessed information from Clinicaltrials.gov to identify any clinical trials of biomarker measurements for the diagnosis of brain damage. In total, we present 41 proteins, enzymes and hormones that have been considered as biomarkers for brain injury, of which 20 have been studied in clinical trials. Several microRNAs have also emerged as potential clinical biomarkers for early diagnosis. Combining multiple biomarkers in a panel, along with other parameters, is yielding promising outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Functional Pharmacology and Neuroscience, Department of Surgical Sciences, Uppsala, University, Uppsala, Sweden.
- Department of Medical Sciences, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.
- Advanced Molecular Technology, Limited Liable Company (LLC), Moscow, 354340, Russia.
- Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. mathias.rask-andersen@igp.uu.se.
Förderung
- Uppsala University
Zitieren
APA
Karimova, D., Rostami, E., Chubarev, V. N., Tarasov, V. V., Schiöth, H. B., & Rask-Andersen, M. (2024). Advances in development of biomarkers for brain damage and ischemia. Molecular Biology Reports, 51(1). https://doi.org/10.1007/s11033-024-09708-x
Vancouver
Karimova D, Rostami E, Chubarev VN, Tarasov VV, Schiöth HB, Rask-Andersen M. Advances in development of biomarkers for brain damage and ischemia. Molecular Biology Reports. 2024;51(1). doi:10.1007/s11033-024-09708-x
BibTeX
@article{Karimova2024,
author = {Karimova, Diana and Rostami, Elham and Chubarev, Vladimir N and Tarasov, Vadim V and Schiöth, Helgi B and Rask-Andersen, Mathias},
title = {Advances in development of biomarkers for brain damage and ischemia},
journal = {Molecular Biology Reports},
year = {2024},
volume = {51},
number = {1},
doi = {10.1007/s11033-024-09708-x}
}
EUVIMED